Accès gratuit
Volume 53, Numéro 2, April-June 2018
Page(s) 101 - 105
Publié en ligne 4 mai 2018
  • Berrington de Gonzalez AB, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E. 2011. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 12: 353–360. [CrossRef] [PubMed] [Google Scholar]
  • Chargari C, Goodman KA, Diallo I, Guy JB, Rancoule C, Cosset JM, Deutsch E, Magne N. 2016. Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models? Cancer Metastasis Rev. 35(2): 277–288. [CrossRef] [PubMed] [Google Scholar]
  • Colin C, Foray N, Di Leo G, Sardanelli F. 2017. Radiation induced breast cancer risk in BRCA mutation carriers from low-dose radiological exposures: a systematic review. Radioprotection 52: 231–240. [CrossRef] [EDP Sciences] [Google Scholar]
  • Cosset JM, Henry-Amar M, Dietrich PY, Socié G, Girinsky T, Hayat M, Tubiana M. 1992. Tumeurs solides secondaires après radiothérapie de la maladie de Hodgkin : expérience de l’institut Gustave-Roussy. Bull. Cancer 79(4): 387–388. [PubMed] [Google Scholar]
  • Cosset JM, Chargari C, Demoor C, Giraud P, Helfre S, Mornex F, Mazal A. 2016. Prévention des cancers radio-induits. Cancer Radiother. 20(Suppl.): S61–S68. [CrossRef] [PubMed] [Google Scholar]
  • Foray N, Bourguignon M, Hamada N. 2016. Individual response to ionizing radiation. Mutat. Res. 770: 369–386. [CrossRef] [PubMed] [Google Scholar]
  • Gray LH. 1957. Radiobiology and cancer. Nature 179(4568): 991–994. [CrossRef] [PubMed] [Google Scholar]
  • Hall E. 2006. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiat. Oncol. Biol. Phys. 65(1): 1–7. [CrossRef] [PubMed] [Google Scholar]
  • Koshy M et al. 2012. Declining use of radiotherapy in stages I and II Hodgkin’s disease and its effect on survival and secondary malignancies. Int. J. Radiat. Oncol. Biol. Phys. 82: 619–620. [CrossRef] [PubMed] [Google Scholar]
  • Kry SF, Bednarz B, Howell RM, Dauer L, Followill D, Klein E, Paganetti H, Wang B, Wuu CS, George Xu X. 2017. AAPM TG 158: measurement and calculation of doses outside the volume from external-beam radiation therapy. Med. Phys. 44(10): e391–e429. [CrossRef] [PubMed] [Google Scholar]
  • Langballe R, Olsen JH, Andersson M, Mellemkjær L. 2011. Risk for second primary non-breast cancer in pre- and postmenopausal women with breast cancer not treated with chemotherapy, radiotherapy or endocrine therapy. Eur. J. Cancer 47: 946–952. [CrossRef] [PubMed] [Google Scholar]
  • Little MP. 2001. Comparison of the risks of cancer incidence and mortality following radiation therapy for benign and malignant disease with the cancer risks observed in the Japanese A-bomb survivors. Int. J. Radiat. Biol. 77(4): 431–464. [CrossRef] [PubMed] [Google Scholar]
  • Peiffert D, Simon JM, Eschwege F. 2007. Epinal radiotherapy accident: passed, present, future. Cancer Radiother. 11(6-7): 309–312. [CrossRef] [PubMed] [Google Scholar]
  • Schneider U. 2011. Modeling the Risk of secondary malignancies after radiotherapy genes. Basel 2(4): 1033–1049. [Google Scholar]
  • Schneider U, Walsh L. 2008. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Radiat. Environ. Biophys. 47(2): 253–63. [CrossRef] [PubMed] [Google Scholar]
  • Somers R, Henry-Amar M, Meerwaldt JH, Carde P. 1990. Treatment strategy in Hodgkin’s disease. John Libbey Eurotext. [Google Scholar]
  • Suit H, et al. 2007. Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat. Res. 167: 12–42. [CrossRef] [PubMed] [Google Scholar]
  • Travis LB, et al. 2002. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J. Natl. Cancer Inst. 94(3): 182–192. [CrossRef] [PubMed] [Google Scholar]
  • Trott KR. 2017. Special radiobiological features of second cancer risk after particle radiotherapy. Phys. Med. 42: 221–227. [CrossRef] [PubMed] [Google Scholar]
  • Tubiana M. 2009. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother. Oncol. 91(1): 4–15. [CrossRef] [PubMed] [Google Scholar]
  • Zelefsky MJ, et al. 2012. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 83(3): 953–959. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.